Eli Lilly and Company (LLY.F)
Chart Events
Performance Outlook
| Previous Close | 308.55 |
| Open | 312.85 |
| Bid | 310.25 x 30000 |
| Ask | 310.55 x 30000 |
| Day's Range | 310.80 - 314.95 |
| 52 Week Range | 257.60 - 373.50 |
| Volume | |
| Avg. Volume | 351 |
| Market Cap | 297.18B |
| Beta (5Y Monthly) | 0.35 |
| PE Ratio (TTM) | 48.30 |
| EPS (TTM) | 6.46 |
| Earnings Date | Apr 27, 2023 |
| Forward Dividend & Yield | 4.27 (1.40%) |
| Ex-Dividend Date | Feb 14, 2023 |
| 1y Target Est | 399.74 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LLY.F
Related Research
- Investor's Business Daily
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
The WHO will consider adding obesity treatments to its "essential medicines list." The move could help shares of Eli Lilly and Novo Nordisk.
- Motley Fool
3 Dividend Stocks That Have Been Paying Investors Since the 1800s
Three businesses that have not only been around for more than a century but have also been paying dividends going back to the 1800s are Eli Lilly (NYSE: LLY), ExxonMobil (NYSE: XOM), and the Toronto-Dominion Bank (NYSE: TD). Healthcare giant Eli Lilly has been paying a dividend since 1885.
- Reuters
UPDATE 1-Boehringer's profit up as Jardiance gains offset higher costs
German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.
